N. Fuente

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

Microtubule-binding agents: a dynamic field of cancer therapeutics

Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Phase II Study of Docetaxel/Vinorelbine in Patients with non—small-Cell-Lung Cancer Previously Treated with Platinum-Based Chemotherapy

A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer.

Gemcitabine (G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC).

Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer